Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

Correction to: Survival in advanced GIST has improved over time and correlates with increased... Call et al. Clin Sarcoma Res (2019) 9:7 Clinical Sarcoma Research https://doi.org/10.1186/s13569-019-0117-2 Open Access CORREC TION Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry 1* 1 1 1 2 Jerry W. Call , Yu Wang , Denisse Montoya , Norman J. Scherzer and Michael C. Heinrich Author details Correction to: Clin Sarcoma Res (2019) 9:4 1 2 Life Raft Group, 155 Route 46 West, Suite 202, Wayne, NJ 07470, USA. Port- https ://doi.org/10.1186/s1356 9-019-0114-5 land VA Health Care System and Knight Cancer Institute, Oregon Health & The legends for Figs.  3 and 5 of the article [1] incor - Science University, Portland, OR, USA. rectly refer to an “all others group”. The corrected legends should read: The original article can be found online at https ://doi.org/10.1186/s1356 9-019-0114-5. Fig. 3 Exploratory analyses of the impact of sunitinib on overall survival. a OS 2nd line, the “No sunitinib” group Publisher’s Note may or may not have had sunitinib later. b OS 2nd line, Springer Nature remains neutral with regard to jurisdictional claims in pub- the “Never sunitinib” group excludes patients that had lished maps and institutional affiliations. sunitinib at a later time. Fig.  5 OS 3rd line, the “Never regorafenib” group excludes patients that had regorafenib at a later time. Regorafenib improved overall survival by 11.9 months in Reference 3rd line treatment compared to best supportive care with 1. Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC. Survival in other TKI’s and excluding no treatment as best support- advanced GIST has improved over time and correlates with increased ive care. Patients that had regorafenib in any treatment access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res. 2019;9:4. https ://doi.org/10.1186/s1356 line were excluded from the “Never regorafenib” group. 9-019-0114-5 A high percentage of patients in “Regorafenib” group were still alive at last follow-up (censored), suggesting an even greater benefit might be possible. Analysis limited to patients reporting progression in 2nd line. *Correspondence: jcall@liferaftgroup.org Life Raft Group, 155 Route 46 West, Suite 202, Wayne, NJ 07470, USA Full list of author information is available at the end of the article © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/ publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Sarcoma Research Springer Journals

Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

Loading next page...
 
/lp/springer-journals/correction-to-survival-in-advanced-gist-has-improved-over-time-and-ueyjmGbX8r

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Biomedicine; Cancer Research; Oncology; Surgical Oncology
eISSN
2045-3329
DOI
10.1186/s13569-019-0117-2
Publisher site
See Article on Publisher Site

Abstract

Call et al. Clin Sarcoma Res (2019) 9:7 Clinical Sarcoma Research https://doi.org/10.1186/s13569-019-0117-2 Open Access CORREC TION Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry 1* 1 1 1 2 Jerry W. Call , Yu Wang , Denisse Montoya , Norman J. Scherzer and Michael C. Heinrich Author details Correction to: Clin Sarcoma Res (2019) 9:4 1 2 Life Raft Group, 155 Route 46 West, Suite 202, Wayne, NJ 07470, USA. Port- https ://doi.org/10.1186/s1356 9-019-0114-5 land VA Health Care System and Knight Cancer Institute, Oregon Health & The legends for Figs.  3 and 5 of the article [1] incor - Science University, Portland, OR, USA. rectly refer to an “all others group”. The corrected legends should read: The original article can be found online at https ://doi.org/10.1186/s1356 9-019-0114-5. Fig. 3 Exploratory analyses of the impact of sunitinib on overall survival. a OS 2nd line, the “No sunitinib” group Publisher’s Note may or may not have had sunitinib later. b OS 2nd line, Springer Nature remains neutral with regard to jurisdictional claims in pub- the “Never sunitinib” group excludes patients that had lished maps and institutional affiliations. sunitinib at a later time. Fig.  5 OS 3rd line, the “Never regorafenib” group excludes patients that had regorafenib at a later time. Regorafenib improved overall survival by 11.9 months in Reference 3rd line treatment compared to best supportive care with 1. Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC. Survival in other TKI’s and excluding no treatment as best support- advanced GIST has improved over time and correlates with increased ive care. Patients that had regorafenib in any treatment access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res. 2019;9:4. https ://doi.org/10.1186/s1356 line were excluded from the “Never regorafenib” group. 9-019-0114-5 A high percentage of patients in “Regorafenib” group were still alive at last follow-up (censored), suggesting an even greater benefit might be possible. Analysis limited to patients reporting progression in 2nd line. *Correspondence: jcall@liferaftgroup.org Life Raft Group, 155 Route 46 West, Suite 202, Wayne, NJ 07470, USA Full list of author information is available at the end of the article © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/ publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Journal

Clinical Sarcoma ResearchSpringer Journals

Published: May 7, 2019

There are no references for this article.